Want to see MLSS full AI Analyst Report?
Top Page
Milestone Scientific
(MLSS)
Select Model
Select Model
Rating:55Neutral
Price Target:
$0.42
▼(-22.22% Downside)
Action:Reiterated
Date:08/17/26
MLSS scores as a higher-risk, improving-trajectory stock: technicals are supportive (price above major moving averages with positive MACD), and the earnings call indicates measurable commercial and reimbursement progress with reaffirmed revenue guidance. Offsetting these positives, financial performance remains the main drag due to large ongoing losses and negative free cash flow, and valuation is constrained by a negative P/E and no indicated dividend support.
Positive Factors
Revenue Growth
Revenue growth across both the quarter and first half indicates improving commercial traction rather than reliance solely on a single reporting period. Reaffirmed full-year guidance and faster expected CompuFlo growth provide a credible basis for continued top-line expansion over the coming quarters.
Negative Factors
Persistent Losses and Cash Burn
The company remains materially unprofitable and is not yet self-funding, despite improving losses and lower historical cash outflows. Continued negative cash generation can restrict investment flexibility and increase reliance on additional financing or further cost reductions to sustain operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Revenue growth across both the quarter and first half indicates improving commercial traction rather than reliance solely on a single reporting period. Reaffirmed full-year guidance and faster expected CompuFlo growth provide a credible basis for continued top-line expansion over the coming quarters.
Read all positive factors
Milestone Scientific (MLSS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$37.23M
Dividend YieldN/A
Average Volume (3M)90.78K
Price to Earnings (P/E)―
Beta (1Y)0.87
Revenue Growth3.72%
EPS Growth43.78%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.05
Shares Outstanding90,644,400
10 Day Avg. Volume72,987
30 Day Avg. Volume90,783
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)7.97
Price to Sales (P/S)2.50
P/FCF Ratio-7.64
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.50Price Target Upside177.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$9.97M
Milestone Scientific Business Overview & Revenue Model
Company Description
Milestone Scientific Inc. is dedicated to the innovation, refinement, and global distribution of advanced diagnostic and therapeutic injection technologies and devices. These solutions cater to the medical, dental, and cosmetic industries, with a ...
Milestone Scientific Earnings Call Summary
Earnings Call Date:Aug 14, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 12, 2026
Earnings Call Sentiment Positive
The call presented multiple clear operational and commercial wins — robust revenue growth, a large percentage increase in medical segment revenue, important Medicare reimbursement milestones, strong third-party clinical validation (91% reduction in complication odds), new federal distribution access, and improved expense discipline that reduced net loss. Offsetting these positives are margin pressure from increased product/import costs, a non-recurring ~ $500K international order that tempers near-term sequential revenue (Q3 guide below Q2), medical revenue still coming from a small base, staffing capacity constraints for lead and reimbursement follow-up, and a modest cash balance that could require monitoring. On balance the call emphasized measurable commercial progress and validation and management provided a path to scale reimbursement and federal channels, while acknowledging operational headwinds to be managed.Positive Updates
Quarterly and Year-to-Date Revenue Growth
Total revenue for Q2 FY2026 was $2.8M, an increase of 22% (+$518K) versus Q2 2025. First half revenue was $5.0M, up 9.8% YoY (+$447K).
Negative Updates
Gross Margin Compression
Gross margin declined to 67.2% in Q2 from 69.6% prior-year (down 2.4 percentage points), driven by product/customer mix and increased product costs including tariffs, tolls and certain import components.
Read all updates
Q2-2026 Updates
Positive
Negative
Quarterly and Year-to-Date Revenue Growth
Total revenue for Q2 FY2026 was $2.8M, an increase of 22% (+$518K) versus Q2 2025. First half revenue was $5.0M, up 9.8% YoY (+$447K).
Read all positive updates
Company Guidance
Management reaffirmed 2026 revenue guidance of $9.8M–$10.2M and said CompuFlo should grow faster than the overall business, after reporting Q2 revenue of $2.8M (up 22% YoY) and H1 revenue of $5.0M (up ~9.8% YoY), with the base business contributing $2.4M and roughly $500K of upside from international orders; Medical segment revenue grew 231% YoY in Q2, supported by a $325 payment established under Novitas and First Coast covering 3 jurisdictions and 13 states (≈30–35% of the U.S. population), while the company noted a UTMB study showing a 91% reduction in odds of composite complications and CompuFlo use at >40 academic centers; Q2 gross profit was $1.9M (67.2% margin), operating expenses were ≈$3.0M (down ~$0.5M or 4.2%), Q2 net loss was $1.1M (vs $1.5M prior), six‑month gross profit was $3.5M (69.4%), six‑month OpEx was $5.4M (down ~$1.4M or 20%), cash was $2.1M with $3.7M working capital and $466K convertible debt (plus a $2.51M private placement in April), the company expects Q3 to be seasonally slower and guided Q3 revenue to roughly $2.3M–$2.5M (noting two large Q2 international orders are not expected to recur), and highlighted commercial traction with 150–200 leads/month (150–200), >40 qualified ASPN leads, a Red One distribution channel reaching ~18M veterans/military beneficiaries, and a plan to take government orders in Q4.Milestone Scientific Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
53
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.42M | 8.97M | 8.63M | 9.83M | 8.81M | 10.30M |
| Gross Profit | 6.56M | 6.33M | 6.43M | 6.79M | 4.90M | 6.31M |
| EBITDA | -3.95M | -5.51M | -4.68M | -6.92M | -8.71M | -6.79M |
| Net Income | -4.14M | -5.72M | -4.71M | -6.93M | -8.71M | -6.82M |
Balance Sheet | ||||||
| Total Assets | 8.35M | 7.81M | 9.80M | 11.37M | 13.70M | 19.81M |
| Cash, Cash Equivalents and Short-Term Investments | 2.07M | 1.11M | 3.26M | 5.95M | 8.72M | 14.76M |
| Total Debt | 615.70K | 1.02M | 349.05K | 395.98K | 497.04K | 586.59K |
| Total Liabilities | 4.88M | 4.99M | 3.96M | 3.36M | 3.70M | 3.59M |
| Stockholders Equity | 3.47M | 2.81M | 5.83M | 8.01M | 10.23M | 16.37M |
Cash Flow | ||||||
| Free Cash Flow | -642.63K | -2.93M | -2.93M | -5.33M | -6.04M | -4.03M |
| Operating Cash Flow | -642.64K | -2.92M | -2.92M | -5.33M | -6.03M | -4.02M |
| Investing Cash Flow | -15.12K | -15.12K | 2.97M | -2.97M | -8.53K | -15.19K |
| Financing Cash Flow | 1.45M | 786.34K | 233.77K | 2.56M | -8.54K | 4.57M |
Milestone Scientific Technical Analysis
Neutral
0.54
Price Trends
0.45
Negative
0.41
Positive
0.35
Positive
Market Momentum
-0.01
Positive
43.95
Neutral
43.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLSS, the sentiment is Neutral. The current price of 0.54 is above the 20-day moving average (MA) of 0.43, above the 50-day MA of 0.45, and above the 200-day MA of 0.35, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 43.95 is Neutral, neither overbought nor oversold. The STOCH value of 43.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MLSS.
Milestone Scientific Risk Analysis
Milestone Scientific disclosed 49 risk factors in its most recent earnings report. Milestone Scientific reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Milestone Scientific Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $45.94M | 26.32 | 16.20% | ― | 24.20% | 28.29% | |
60 Neutral | $50.67M | -6.97 | -37.47% | ― | 64.18% | 28.90% | |
55 Neutral | $37.23M | -8.61 | -149.08% | ― | 3.72% | 43.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $20.95M | -5.81 | -4.59% | ― | -11.16% | 59.85% | |
45 Neutral | $20.77M | -0.54 | -225.98% | ― | 21.86% | 73.27% | |
40 Underperform | $2.15M | -0.25 | -133.10% | ― | 3.38% | -78.48% |
* Healthcare Sector Average
MLSS
Milestone Scientific
0.41
-0.05
-10.09%
RVP
Retractable Technologies
0.70
-0.12
-14.76%
POCI
Precision Optics Corporation
4.63
0.24
5.47%
NEPH
Nephros
4.23
-0.34
-7.44%
FEMY
Femasys
2.48
-4.56
-64.77%
NXGL
NexGel Inc
0.17
-2.25
-92.81%
Milestone Scientific Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Milestone Scientific Shareholders Approve Governance and Equity Changes
Positive
Jul 31, 2026
On June 20, 2026, Milestone Scientific’s board elected Kelly Ulto and Greg Shilling as directors to fill vacancies, then re-elected them effective July 27, 2026 to serve until the 2027 annual meeting, reaffirming their independence under NYS...
Private Placements and FinancingRegulatory Filings and Compliance
Milestone Scientific Directors Elect Conversion of Bridge Notes
Neutral
Jul 29, 2026
On July 24, 2026, Milestone Scientific Inc. received conversion notices from directors Benedetta Casamento, Dr. Didier Demesmin and Neal Goldman regarding their amended and restated Convertible Bridge Notes, originally issued in an aggregate princ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.